# DUO-E (NCT04269200)

> Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04269200
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Endometrial Neoplasms
- Interventions: olaparib; durvalumab; durvalumab placebo; olaparib placebo; Carboplatin; Paclitaxel
- Enrollment: 805
- Primary outcome: Progression-free Survival (PFS) According to RECIST 1.1, Based on Investigator Assessments

## Commentary we found

- YouTube: 80
- Podcasts: 51
- X threads: 25
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=duo-e-nct04269200

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04269200", "email": "<work email>"}; the inbox owner confirms by the emailed link.